Imbalance in the components of the cartilage of the joint leads to its chondromalacia. This pathology requires a complex effect. Along with physical rehabilitation, physiotherapy, and the use of drugs, the composition of which includes glucosamine and chondroitin, the drug Alflutop is widely used in clinical practice. It contains the main components of the cartilage matrix. Alflutop (tablets) is not produced. The drug is available in ampoules.
According to many experts, the drug Alflutop is an effective “catalyst” that starts the regeneration of cartilage tissue. In addition, studies have shown that the use of the medication significantly reduces the need for patients to use NSAIDs.
Means "Alflutop" describes the instruction as a drug that helps regulate metabolic processes in cartilage tissue.
The chondroprotective effect of the drug is based on the normalization of the biosynthesis of collagen of the second type and hyaluronic acid, the inhibition of the activity of hyaluronidase and other enzymes involved in the destruction of cartilage.
Due to the restoration of homeostasis in the joint, Alflutop drug delays the biosynthesis of inflammatory mediators, including cytokines. As a result, an analgesic and anti-inflammatory effect develops, manifested on the eighth to tenth day of the start of therapy.
The proteoglycans that make up the Alflutop preparation have a substitution effect, have a trophic effect, and increase hydrophilicity, uniformity of bone tissue and cartilage height.
The drug is prescribed for degenerative and rheumatic pathologies. In particular, the medicine "Alflutop" instruction recommends for spondylosis, osteoarthritis of different localization (arthrosis of small joints, gonarthrosis, coxarthrosis). A medication is prescribed in the rehabilitation period after surgical interventions and joint injuries.
The drug "Alflutop" instruction allows for use only in adults.
The introduction is carried out deep inside the muscle. Typically, the dosage is one milliliter once a day. The course lasts twenty days.
With lesions in a large joint, administration is carried out inside it. The maximum dosage of Alflutop is 2 ml every three days. The duration of the course is five injections in each joint.
If necessary, and the availability of evidence, conduct repeated courses after three or six months.
The drug "Alflutop" instruction does not admit to the appointment for individual intolerance. Do not prescribe a remedy for pregnant and lactating women.
When using the medicine, adverse reactions are possible. The drug can provoke a burning sensation at the injection site, flushing of the skin, dermatitis, myalgia (short-term). With intra-articular administration, in some cases, an increase in pain intensity was noted (as a result of increased blood supply and activation of metabolism). An allergy to the drug was extremely rare: rashes, urticaria, swelling of the neck, palpitations, shortness of breath, agitation. Some patients showed the development of a fear of death, swelling of the legs, general weakness. Alflutop can also cause anaphylactic shock.
In the presence of autoimmune pathologies, the use of the drug is carried out strictly under medical supervision.
Alflutop medicine does not affect the ability to drive vehicles.
With the simultaneous administration of the drug with local anesthetic medicines, primarily with PABA derivatives (the Procain drug, for example), it is necessary to take into account the likelihood of side effects of the latter.
Before using Alflutop, you should consult your doctor.